ConductScience.org, home

Paper2199402

A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy. An Eastern Cooperative Oncology Group pilot study.

Trump DL and 6 others. Invest New Drugs, 1990. Cited by 27 papers, by iCite.

Cite this record

ConductScience Library. A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy. An Eastern Cooperative Oncology Group pilot study. Papers, record 2199402. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2199402

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy. An Eastern Cooperative Oncology Group pilot study.
PubMed
Journal
Invest New Drugs
PubMed
Year
1990
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
27
iCite
Relative citation ratio, by iCite
0.71
iCite
Revised in PubMed
2019-10-22
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Trump DLD L
2Marsh JCJ C
3Kvols LKL K
4Citrin DD
5Davis TET E
6Hahn RGR G
7Vogl SES E

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Organoplatinum CompoundsMajor topic
Prostatic NeoplasmsMajor topic
Bone Neoplasms
Carboplatin
Drug Evaluation
Humans
Male
Pilot Projects

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
CA 21115NCI NIH HHSUnited StatesR10CA021115PubMed and NIHNIH RePORTER
U10CA021115NIHNIH RePORTER

Download CSV of grants

References9

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
1442343Treatment of estrogen-resistant stage D carcinoma of prostate with cis diamminedichloroplatinum.Urology1979https://conductscience.org/library/papers/442343PubMed
26422006Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer.J Clin Oncol1983https://conductscience.org/library/papers/6422006PubMed
36374169Phase II trial of doxorubicin in bidimensionally measurable prostatic adenocarcinoma.J Urol1984https://conductscience.org/library/papers/6374169PubMed
47194733Cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil in advanced prostatic cancer: a randomized trial.Cancer1981https://conductscience.org/library/papers/7194733PubMed
5498150Antileukemia (L1210) activity and toxicity of cis-dichlorodiammineplatinum(II) analogs.Cancer Treat Rep1979https://conductscience.org/library/papers/498150PubMed
6498029A critical analysis of response criteria in patients with prostatic cancer treated with cis-diamminedichloride platinum II.Cancer1979https://conductscience.org/library/papers/498029PubMed
76340081A comparative clinical trial of adriamycin and 5-fluorouracil in advanced prostatic cancer: prognostic factors and response.Prostate1983https://conductscience.org/library/papers/6340081PubMed
8765499Aminoglutethimide medical adrenalectomy for advanced prostatic carcinoma.J Urol1976https://conductscience.org/library/papers/765499PubMed
93894584Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?J Clin Oncol1985https://conductscience.org/library/papers/3894584PubMed

Download CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 27 citations.

PMIDTitleJournalYearIn PapersSource
34631559A Case Report of Metastatic Castration-Resistant Prostate Cancer Harboring a PTEN Loss.Front Oncol2021https://conductscience.org/library/papers/34631559PubMed
29063869Role of chemotherapy in prostate cancer.Asian J Androl2018https://conductscience.org/library/papers/29063869PubMed
25755690Isorhamnetin flavonoid synergistically enhances the anticancer activity and apoptosis induction by cis-platin and carboplatin in non-small cell lung carcinoma (NSCLC).Int J Clin Exp Pathol2015https://conductscience.org/library/papers/25755690PubMed
8738624Etoposide, epirubicin and carboplatin in hormone-refractory prostate cancer.Int Urol Nephrol1996https://conductscience.org/library/papers/8738624PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/2199402

GET https://conductscience.org/api/papers/v1/2199402/authors